Turnstone Biologics Corp (TSBX): Debt to Equity

Turnstone Biologics (TSBX) owns a high-tech cGMP facility in California, ensuring the independent production of viral vectors. Meanwhile, management is currently aggressively optimizing costs and R&D to preserve liquidity. The price action on the total debt-to-equity chart recorded a value of 0.03. The business relies on the development of personalized tumor-fighting methods, which guarantees exceptional pricing power over therapy costs following certification.

Turnstone Biologics' development of innovative TIL vaccines for solid tumor therapy requires significant capital expenditures, making debt load control critically important. This debt-to-equity chart compares total liabilities with equity, allowing investors to assess financial stability and the risk of excessive leverage while scaling the business within the immuno-oncology segment.